Page 18 - Flipbook
P. 18
Uncomfortable issues
The efficacy of cisplatin doesn’t look in a different league to carboplatin.
Immune checkpoint inhibitors seem active irrespective of cisplatin eligibility.
The principal of the ‘unmet need’ may have hindered out progress.
The PD-L1 doesn't exist as a single entity. It hasn’t been helpful in selecting patients for
therapy.
Immune checkpoint inhibitors are active in selected patients with urothelial
cancer. Selecting patients based on cisplatin eligibility and PD-L1 status is not
supported by the data in my opinion.
